Saturday 17 October 2026
Export PRME’s income statement to Excel — free account
Prime Medicine, Inc.
PRME Healthcare Biotechnology
Prime Medicine, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.6 million, up 55.3% from fiscal 2024. In the quarter to June 2026, revenue grew 3.50%, EPS grew 41.5% and free cash flow grew 4.40%, each against the same quarter a year earlier.
3.47
0.14
−3.88%
Follow PRME
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (373.29%) | (216.07%) | (146.81%) | (112.34%) |
+8 more TTM periods Free account |
|
| (71.16%) | (63.69%) | (62.83%) | (54.98%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(228.61%) | (164.74%) | (122.34%) | (90.34%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.88) | (0.90) | (1.12) | (0.72) | |
Free Cash Flow |
(156.85) | (158.74) | (167.09) | (115.09) | |
Capital Expenditures |
(0.80) | (2.32) | (4.53) | (6.03) | |
| Other line items | |||||
Cash ROIC |
(116.29%) | (74.81%) | (55.97%) | (30.68%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
3,589.52% | 3,821.99% | 3,467.96% | 2,677.45% | |
Selling, General and Administrative Expense of Revenue |
1,335.43% | 1,399.78% | 1,130.09% | 835.03% | |
Share Based Compensation of Revenue |
657.28% | 699.83% | 631.87% | 513.54% | |
Operating CF/Net income |
0.83 | 0.79 | 0.81 | 0.55 | |
Depreciation/Fixed assets |
0.31 | 0.28 | 0.26 | 0.27 | |
Capex/Depreciation |
(0.15) | (0.44) | (0.84) | (1.03) | |
Revenue per Share |
0.02 | 0.02 | 0.03 | 0.04 | |
Operating CF per Share |
(0.88) | (0.88) | (1.09) | (0.68) | |
Capex per Share |
0.00 | (0.01) | (0.03) | (0.04) | |
Capex to Sales |
0.20 | 0.58 | 0.98 | 1.01 |
Columns are period end dates